Skip to main content

Table 1 Corticosteroid exposure post-randomization, modified intention-to-treat population

From: Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial

 

Placebo

Atacicept 75 mg

Atacicept 150 mg

 

( n = 154)

( n = 157)

( n = 144)

Zero dose increases, n (%)

108 (70.1)

115 (73.2)

122 (85.3)

 

(n = 154)

(n = 157)

(n = 143)

Corticosteroids ≥20 mg/day, n (%)

43 (27.9)

39 (24.8)

17 (11.9)

Odds ratio

 

0.860

0.346

P value

 

0.563

0.001

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us